Aktienanalyse zu Intelligent Bio Solutions Inc (INBS)INBSIntelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Intelligent Bio Solutions Inc (INBS) is currently trading at $2.36, which is significantly lower than its 200-day simple moving average of $4.526. The stock has a low RSI of 44.12, indicating it is not yet oversold, but it has shown a substantial decline of 70.09% year-to-date. Although there are positive catalysts such as the recent ISO certification and advancements in clinical studies, the overall financial performance remains concerning with a net income loss of $3,907,667 in the last quarter. The main risk is the company's high net margin loss of -341.89% in Q4 2026, which raises questions about its profitability and sustainability in the long term.